Abstract: The present invention provides a pharmaceutical composition in the form of a water-containing cream which contains at least one glycyrrhetinic acid derivative (as hereinbefore defined), together with at least one non-toxic, water-soluble salt of zinc, calcium and/or magnesium as stabilizer.

Abstract: The present invention provides an enzyme which is an odorless, white powder, the pH of a 15000 to 22000 IU/ml. solution of which in carbon dioxide-free physiological saline solution suitable for injection is 4.5 to 7.5, the solution being clear and colorless; a solution of 50000 IU of which in 3 ml. carbon dioxide-free physiological saline solution suitable for injection has a light absorption of not more than 0.60 at 280 nm and of not more than 0.37 at 260 nm; the enzyme having the following percentage amino acid analysis:______________________________________ Asp 11.1 .+-. 0.4; Thr 5.8 .+-. 0.1; Ser 6.4 .+-. 0.2; Glu 9.1 .+-. 0.2; Pro 5.0 .+-. 0.5; Gly 6.6 .+-. 0.2; Ala 7.4 .+-. 0.1; Val 7.9 .+-. 0.5; Met 0.8 .+-. 0.1; Ile 5.2 .+-. 0.2; Leu 10.9 .+-. 0.2; Tyr 4.4 .+-. 0.1; Phe 4.5 .+-. 0.1; His 2.8 .+-. 0.2; Lys 7.6 .+-. 0.4; Arg 5.6 .+-. 0.1; ______________________________________said enzyme having a total hexose content of 10.6.+-.0.003%; said enzyme containing not more than 5 .mu.g.

Abstract: The present invention provides a water-soluble or water-dispersible particulate pharmaceutical composition comprising, per one part by weight of glycyrrhetinic acid and/or glycyrrhetinic acid derivative (as hereinbefore defined), 10 to 100 parts by weight of lactose and/or sorbitol, 10 to 50 parts by weight of at least one buffer selected from sodium citrate, potassium citrate, sodium tartrate, potassium tartrate, sodium malate and potassium malate and 0.1 to 10 parts by weight of disodium edetate.

Abstract: There is provided a pharmaceutical composition in dosage unit form comprising (a) 1 - 100 mg. of glycyrrhetinic acid and/or of at least one anti-inflammatory active derivative thereof, in admixture with (b) 1 - 50% by weight of alginic acid and/or at least one non-toxic salt thereof and/or of at least one carboxyalkyl-cellulose and/or of at least one non-toxic salt thereof, (c) 1 - 30% by weight of at least one non-toxic carbonate and/or bicarbonate and (d) 0 - 30% by weight of at least one antacid compound.